DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2011; 136(36): 1789DOI: 10.1055/s-0031-1286103 Pro & Contra | CommentaryGastroenterologie© Georg Thieme Verlag KG Stuttgart · New YorkBiologika als Erstlinientherapie bei chronisch entzündlichen Darmerkrankungen – contraBiologicals first-line in chronic inflammatory bowel disease? NoK. Herrlinger1 , E. F. Stange1 1Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Robert-Bosch-Krankenhaus Stuttgart Recommend Article Abstract Buy Article(opens in new window) Schlüsselwörter chronisch entzündliche Darmerkrankungen - Morbus Crohn - Biologika - Erstlinientherapie Keywords chronic inflammatory bowel disease - Crohn's disease - biologicals - first-line therapy Full Text References Literatur 1 Colombel J F. et al . Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010; 362 1383-1395 2 Hanauer S B. et al . Maintenance infliximab for Crohn’s disease. Lancet. 2002; 359 1541-1549 3 Colombel J F. et al . Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease. Gastroenterology. 2007; 132 52-65 4 D’Haens G. et al . Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease. Lancet. 2008; 371 660-667 5 Cullen G, Keegan D, Mulcahy H E, O’Donoghue D P. A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn’s disease. Clin Gastroenterol Hepatol. 2009; 7 323-328 6 Cottone M. et al . Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9 30-35 Prof. Dr. Eduard Stange Abteilung für Gastroenterologie, Hepatologie und EndokrinologieRobert-Bosch-Krankenhaus Auerbachstr. 110 70376 Stuttgart Email: eduard.stange@rbk.de
